Although this field is still at the dawn, clinical evaluations of liver metabolism and metabolic signatures combined with insulin sensitizers for the treatment of patients with AIP presenting with metabolic disturbances such as glucose intolerance, IR, obesity, and T2DM may potentially sustain the hepatic absorption and maintenance of glucose homeostasis from dietary carbohydrates, thereby improving liver function. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.